Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial

Clinical outcomes for glioblastoma remain poor. Treatment with immune checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from a randomized phase 3 clinical trial evaluating a programmed death-1 (PD-1) inhibitor therapy for glioblastoma have not been reported. To dete...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	JAMA oncology Ročník 6; číslo 7; s. 1003
Hlavní autoři:	Reardon, David A, Brandes, Alba A, Omuro, Antonio, Mulholland, Paul, Lim, Michael, Wick, Antje, Baehring, Joachim, Ahluwalia, Manmeet S, Roth, Patrick, Bähr, Oliver, Phuphanich, Surasak, Sepulveda, Juan Manuel, De Souza, Paul, Sahebjam, Solmaz, Carleton, Michael, Tatsuoka, Kay, Taitt, Corina, Zwirtes, Ricardo, Sampson, John, Weller, Michael
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.07.2020
Témata:	Adult Aged Angiogenesis Inhibitors - adverse effects Angiogenesis Inhibitors - therapeutic use Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Bevacizumab - adverse effects Bevacizumab - therapeutic use Brain Neoplasms - drug therapy Brain Neoplasms - genetics Brain Neoplasms - mortality Brain Neoplasms - radiotherapy DNA Modification Methylases - genetics DNA Repair Enzymes - genetics Female Glioblastoma - drug therapy Glioblastoma - genetics Glioblastoma - mortality Glioblastoma - radiotherapy Humans Immune Checkpoint Inhibitors - adverse effects Immune Checkpoint Inhibitors - therapeutic use Male Middle Aged Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - mortality Nivolumab - adverse effects Nivolumab - therapeutic use Programmed Cell Death 1 Receptor - antagonists & inhibitors Temozolomide - therapeutic use Treatment Outcome Tumor Suppressor Proteins - genetics Young Adult
ISSN:	2374-2445, 2374-2445
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!